Eva Polverino

List of Publications by Year in descending order

99 papers	6,080 citations	100601 38 h-index	84171 75 g-index
102 all docs	102 docs citations	102 times ranked	4960 citing authors

#	Article	IF	Citations
1	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respiratory Medicine,the, 2022, 10, 298-306.	5.2	70
2	Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19. Chest, 2022, 161, 647-650.	0.4	15
3	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	2.5	67
4	Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients. ERJ Open Research, 2022, 8, 00388-2021.	1.1	3
5	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the â€œChronic Obstructive Pulmonary Diseaseâ€“Bronchiectasis Associationâ€• American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426.	2.5	29
6	Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 2021, 73, e256-e259.	2.9	16
7	Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. Journal of Cystic Fibrosis, 2021, 20, 388-394.	0.3	21
8	Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. European Respiratory Journal, 2021, 57, 2001451.	3.1	30
9	Comorbidities and mortality risk factors for patients with bronchiectasis. Expert Review of Respiratory Medicine, 2021, 15, 623-634.	1.0	9
10	ImplementaciÃ³n de un panel de genes para el diagnÃ³stico genÃ©tico de la discinesia ciliar primaria. Archivos De Bronconeumologia, 2021, 57, 186-194.	0.4	5
11	Implementation of a gene panel for genetic diagnosis of primary ciliary dyskinesia. Archivos De Bronconeumologia, 2021, 57, 186-194.	0.4	8
12	Coordinated Response to Imported Vaccine-Derived Poliovirus Infection, Barcelona, Spain, 2019â€“2020. Emerging Infectious Diseases, 2021, 27, 1513-1516.	2.0	2
13	Long-term Follow-up in Adult Patients with Cystic Fibrosis and Deep Intronic Splicing Variants. Archivos De Bronconeumologia, 2021, 57, 501-503.	0.4	0
14	ROSE: radiology, obstruction, symptoms and exposure â€“ a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Research, 2021, 7, 00399-2021.	1.1	19
15	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
16	Safety, diagnostic, and therapeutic value of flexible bronchoscopy in critically ill COVID-19 patients. Canadian Journal of Anaesthesia, 2021, 68, 434-435.	0.7	12
17	Can we Train the Immune System of Patients With Cystic Fibrosis?. Archivos De Bronconeumologia, 2021, 57, 708-710.	0.4	0
18	Can we Train the Immune System of Patients With Cystic Fibrosis?. Archivos De Bronconeumologia, 2021, 57, 708-710.	0.4	0

#	Article	IF	Citations
19	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research, 2021, 7, 00807-2020.	1.1	8
20	Lung Ultrasound as a First-Line Test in the Evaluation of Post-COVID-19 Pulmonary Sequelae. Frontiers in Medicine, 2021, 8, 815732.	1.2	9
21	Immunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia. Journal of Clinical Medicine, 2020, 9, 3603.	1.0	7
22	New opacities in lung allograft after transbronchial cryobiopsy. Respiratory Medicine, 2020, 170, 106043.	1.3	2
23	Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. Respiratory Care, 2020, 65, 1478-1487.	0.8	3
24	Long-term Follow-up in Adult Patients with Cystic Fibrosis and Deep Intronic Splicing Variants. Archivos De Bronconeumologia, 2020, 57, 501-501.	0.4	0
25	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	2.9	116
26	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology and Therapeutics, 2019, 58, 101834.	1.1	8
27	Inhaled Treatments and the Future of Respiratory Diseases: Holding Our Breath. Respiration, 2019, 97, 498-500.	1.2	2
28	Bronchiectasis in severe asthma. Current Opinion in Pulmonary Medicine, 2019, 25, 71-78.	1.2	16
29	Micobacterias atÃpicas en las bronquiectasias: Â¿cuÃ¡ndo tratar?. Archivos De Bronconeumologia, 2019, 55, 183-184.	0.4	0
30	Bronchiectasis phenotypes. Current Opinion in Pulmonary Medicine, 2019, 25, 281-288.	1.2	10
31	Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. Journal of Cystic Fibrosis, 2019, 18, 525-529.	0.3	43
32	RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. European Respiratory Journal, 2018, 51, 1702052.	3.1	146
33	RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. European Respiratory Journal, 2018, 51, 1702053.	3.1	144
34	The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	3.1	150
35	Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. European Respiratory Journal, 2018, 51, 1701937.	3.1	23
36	Characterization of the â€œFrequent Exacerbator Phenotypeâ€•in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	2.5	215

#	Article	IF	Citations
37	Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 79-87.	0.4	57
38	The BRICS (Bronchiectasis Radiologically Indexed CT Score). Chest, 2018, 153, 1177-1186.	0.4	44
39	Spanish Guidelines on Treatment of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 88-98.	0.4	107
40	Normativa sobre la valoraciÃ³n y el diagnÃ³stico de las bronquiectasias en el adulto. Archivos De Bronconeumologia, 2018, 54, 79-87.	0.4	71
41	Normativa sobre el tratamiento de las bronquiectasias en el adulto. Archivos De Bronconeumologia, 2018, 54, 88-98.	0.4	98
42	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. European Respiratory Journal, 2018, 52, 1802074.	3.1	26
43	Bronchiectasis and Chronic Airway Disease. Chest, 2018, 154, 737-739.	0.4	41
44	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	3.1	138
45	Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661878738.	1.0	11
46	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. Journal of Infection, 2018, 77, 99-106.	1.7	17
47	Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 281-289.	0.7	32
48	Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry. , 2018, , .		3
49	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE, 2018, 13, e0191721.	1.1	81
50	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. Chest, 2017, 151, 1311-1319.	0.4	13
51	Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. Journal of Infection, 2017, 74, 442-449.	1.7	9
52	Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis. Chronic Respiratory Disease, 2017, 14, 360-369.	1.0	18
53	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. Chest, 2017, 152, 249-262.	0.4	158
54	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	3.1	253

#	Article	IF	Citations
55	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. Respiratory Research, 2017, 18, 176.	1.4	30
56	Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe, 2017, 13, 194-207.	0.6	20
57	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
58	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	0.6	34
59	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	3.1	63
60	Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. Archivos De Bronconeumologia, 2017, 53, 366-374.	0.4	36
61	Acute exacerbations of COPD: risk factors for failure and relapse. International Journal of COPD, 2017, Volume 12, 2687-2693.	0.9	37
62	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS ONE, 2017, 12, e0175171.	1.1	32
63	Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. European Respiratory Journal, 2016, 48, 797-807.	3.1	36
64	The best of respiratory infections from the 2015 European Respiratory Society International Congress. ERJ Open Research, 2016, 2, 00049-2016.	1.1	0
65	The Importance of Phenotyping Bronchiectasis. Respiration, 2016, 92, 134-135.	1.2	1
66	Efficacy and Tolerability of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in Bronchiectasis (Non-CF Etiology): Results From the Phase III RESPIRE 1 Study. Chest, 2016, 150, 1315A.	0.4	5
67	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal, 2016, 48, 632-647.	3.1	170
68	Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiratory Medicine, 2016, 117, 179-189.	1.3	70
69	Community acquired pneumonia in asthma: Not a threatening combination. Respiratory Medicine, 2016, 112, 136.	1.3	0
70	Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Chronic Respiratory Disease, 2016, 13, 128-136.	1.0	32
71	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	1.1	133
72	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. Journal of Infection, 2015, 71, 28-36.	1.7	20

#	Article	IF	Citations
73	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. European Respiratory Journal, 2015, 45, 1353-1363.	3.1	42
74	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. JAMA - Journal of the American Medical Association, 2015, 313, 677.	3.8	428
75	Etiology of Nonâ€“Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	1.5	233
76	Inhaled corticosteroids and systemic inflammatory response in communityâ€acquired pneumonia: A prospective clinical study. Respirology, 2014, 19, 929-935.	1.3	20
77	HCAP. Clinical Pulmonary Medicine, 2014, 21, 113-119.	0.3	0
78	Authorâ€™s response to â€˜CAP and HCAP are different? An unresolved questionâ€™. Thorax, 2014, 69, 677-678.	2.7	1
79	A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia. Respiratory Care, 2014, 59, 1078-1085.	0.8	41
80	Severity and outcomes of community acquired pneumonia in asthmatic patients. Respiratory Medicine, 2014, 108, 1713-1722.	1.3	14
81	Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. European Respiratory Journal, 2014, 43, 1698-1708.	3.1	58
82	Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1241-1248.	2.5	48
83	Systemic corticosteroids for communityâ€acquired pneumonia: Reasons for use and lack of benefit on outcome. Respirology, 2013, 18, 263-271.	1.3	31
84	Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal, 2013, 41, 1107-1115.	3.1	181
85	Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia. Chest, 2013, 143, 767-775.	0.4	47
86	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, caseâ€“control study. Thorax, 2013, 68, 1007-1014.	2.7	77
87	Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia. Chest, 2013, 144, 999-1007.	0.4	162
88	Invasive Pneumococcal Disease Today. Clinical Pulmonary Medicine, 2012, 19, 191-198.	0.3	4
89	Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia. Chest, 2012, 141, 1537-1545.	0.4	86
90	Community-acquired pneumonia in outpatients: aetiology and outcomes. European Respiratory Journal, 2012, 40, 931-938.	3.1	64

#	Article	IF	Citations
91	Does health care associated pneumonia really exist?. European Journal of Internal Medicine, 2012, 23, 407-411.	1.0	11
92	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. Journal of Infection, 2012, 65, 223-230.	1.7	77
93	Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax, 2011, 66, 340-346.	2.7	259
94	Patientsâ€™ characterization, hospital course and clinical outcomes in five Italian respiratory intensive care units. Intensive Care Medicine, 2010, 36, 137-142.	3.9	52
95	Current Perspective of the HCAP Problem: Is It CAP or Is It HAP?. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 239-248.	0.8	19
96	Urban Residence Is Associated With Bronchial Hyperresponsiveness in Italian General Population Samples. Chest, 2009, 135, 434-441.	0.4	15
97	Diagnostic Strategies for Healthcare-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 036-045.	0.8	18
98	Severe Communityâ€Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. Clinical Infectious Diseases, 2009, 48, 377-385.	2.9	154
99	Gas Exchange Response to Short-Acting Î²2-Agonists in Chronic Obstructive Pulmonary Disease Severe Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 350-355.	2.5	24